Microcap Ledger Liminatus Pharma, Inc. $LIMN
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Cerritos, CA
- Fiscal year end
- December 31
- Shares outstanding
- 67,160,362 [10-Q 2026-08-14]
What the company doesAI summary of filing
Liminatus Pharma, Inc. is a pre-clinical stage biopharmaceutical company developing a humanized anti-CD47 monoclonal antibody (IBA101) for cancer treatment. The company's product candidate targets the CD47 immune checkpoint, which it says enables cancer cells to evade the immune system, and is designed to preferentially bind to immune cells rather than red blood cells and platelets, addressing a safety issue seen in earlier CD47 therapies. Liminatus is not currently generating revenue and is preparing for IND application submission with a Phase 1 clinical trial scheduled for 2026. The company manufactures through third-party GMP-compliant manufacturers and generates no current revenue. [10-K 2026-03-31]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$2.53M | −$2.99M | $3.02M | [10-Q 2026-08-14] |
| FY ended Dec 2025 | — | −$10.21M | −$9.96M | $337.7K | [S-1 2026-06-24] |
| FY ended Dec 2024 | — | −$3.55M | −$1.45M | $0.00 | [S-1 2026-06-24] |
- Quarterly cash burn
- −$1.49M
- Cash runway Estimate
- ~6.1 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2025-05-30 | 26,014,633 | [10-Q 2025-06-02] |
| 2025-10-03 | 27,064,633 | [10-Q 2025-10-06] |
| 2025-11-13 | 27,064,633 | [10-Q 2025-11-14] |
| 2026-03-27 | 44,877,633 | [10-K 2026-03-31] |
| 2026-05-14 | 44,877,633 | [10-Q 2026-05-15] |
| 2026-08-14 | 67,160,362 | [10-Q 2026-08-14] |
- Shelf registration
- S-1 filed 2026-06-24; no effectiveness notice found in EDGAR [S-1 2026-06-24]
Listing status
Current status: 8 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-09-29. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-09-29 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-09-29] |
| 2026-08-18 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-08-18] |
| 2026-07-24 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-07-24] |
| 2026-05-27 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-05-27] |
| 2026-01-26 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-01-26] |
| 2025-11-25 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-11-25] |
| 2025-08-25 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-08-25] |
| 2025-06-04 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-06-04] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-07-02 | Valetudo Therapeutics Llc | other | 3,448,926 | — | [4 2026-07-14] |
| 2026-06-24 | Valetudo Therapeutics Llc | other | 4,373,603 | — | [4 2026-07-06] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-29 | 8-K | Listing notice or transfer; Regulation FD disclosure |
| 2026-08-18 | 8-K | Listing notice or transfer; Change to security holder rights; Charter, bylaws or fiscal year change |
| 2026-08-14 | 10-Q | Quarterly report |
| 2026-08-04 | 8-K | Shareholder vote results |
| 2026-07-30 | 8-K | Other events |
| 2026-07-24 | 8-K | Listing notice or transfer; Other events |
| 2026-07-22 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-07-14 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-07-13 | DEF 14A | Proxy statement |
| 2026-07-06 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-07-06 | 8-K | Material agreement entered; Acquisition or disposition completed; Unregistered sale of equity |
| 2026-06-30 | PRE 14A | Proxy statement |
Alerts for $LIMN
Email me when Liminatus Pharma, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.